medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2015, Number 4

<< Back Next >>

Rev Mex Patol Clin Med Lab 2015; 62 (4)

Neisseria meningitidis cases in third level hospital

Gaona-Flores VA, Alcalá-Martínez E, Becerra-Fragoso J, Cortés-Arredondo K, Campos-Navarro LA

Language: English
References: 15
Page: 240-244
PDF size: 220.69 Kb.


ABSTRACT

Background: Neisseria meningitidis is a Gram-negative bacterium. Serotypes associated with it are A, B, C, and W-135. And they can appear at any age. From 2002-2010, 474 cases were reported in Mexico. The Ministry of Health is the Health Care Institution attending more cases (64%) and the Instituto Mexicano del Seguro Social attends 11.18%. Objective: Retrospective analysis of clinical and bacteriological aspects of cases meningitis by N. meningitidis treated at the Infectology Hospital, during the period 2010-2013. Methods: Descriptive study, in a reference center for infectious diseases. All patients with a confirmed infection due to N. meningitidis diagnosis were included. The information was obtained from the epidemiological study conducted. Results: There were a total of 11 confirmed cases of infection due to N. meningitidis; the diagnosis was made by coagglutination test, and serotype C predominated. Conclusion: The main measures for disease control are accurate diagnosis, ideally with microbiological culture, timely treatment and chemoprophylaxis. Conjugated vaccines have shown a good population impact due to its effect on decreasing the percentage of asymptomatic carriers. In order to evaluate prior exposure with greater precision, it is appropriate to study the presence of N. meningitidis in all close contacts.


REFERENCES

  1. Almeida-González L, Franco-Paredes C, Pérez LF, Santos-Preciado JI. Enfermedad por meningococo, Neisseria meningitidis: perspectiva epidemiológica, clínica y preventiva. Salud Pública de México. 2004; 46 (5): 438-450.

  2. Centers for Disease Control and Prevention. Meningococcal disease (page last updated: April 1, 2014) [consult 2014 July 2]. Available in: http://www.cdc.gov/meningococcal/about/symptoms.html

  3. Chiavetta L, Chávez E, Ruiz A, Mollerach M, Reguera M. Vigilancia de Neisseria meningitidis en Argentina, 1993-2005: distribución de serogrupos, serotipos y serosubtipos causantes de enfermedad invasiva. Rev Argent Microbiol. 2007; 39 (1): 21-27.

  4. Ibarz AB, Lemos AP, Gorla MC, de Cunto-Brandileone MC. Diagnóstico de laboratorio de las meningitis bacterianas causadas por Neisseria meningitidis. En: Manual de procedimientos de laboratorio de la red SIREVA II. São Paulo, Brasil: Organización Panamericana de la Salud; 2011. pp. 34-36.

  5. Kellerman SE, McCombs K, Ray M, Baughman W, Reeves MW, Popovic T et al. Genotype specific carriage of Neisseria meningitidis in Georgia countries with hyper and hypo sporadic rates of meningococcal disease. J Infect Dis. 2002; 186: 40-48.

  6. Leggiadro RJ. Effect of vaccines on bacterial meningitis worldwide. Pediatr Infect Dis J. 2013; 32: 360-361.

  7. Leimkugel J, Adams-Forgor A, Gagneux S, Pflüger V, Flierl C, Awine E et al. An outbreak of serotype 1 Streptococcus pneumoniae meningitis in nothern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemic. J Infect Dis. 2005; 192 (2): 192-199. doi: 10.1086/431151.

  8. Mayer LW, Reeves MW, Al Hamdan A, Sacchi CT, Taha MK, Ajello GW et al. Outbreak of W-135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type 37 complex. J Infect Dis. 2002; 185: 1596-1605.

  9. McIntyre PB, O’Brien KL, Greenwood B, van de Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet. 2012; 380: 1703-1711.

  10. Peltola H, Leib SL. Performance of adjunctive therapy in bacterial meningitis depends on circumstances. Pediatr Infect Dis. J 2013; 12: 1381-1382.

  11. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2000; 49 (RR07): 1-10.

  12. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2003; 344: 1378-1388. doi: 10.1056/NEJM200105033441807.

  13. Secretaría de Salud. Boletín Epidemiológico. Número 13 | Volumen 30 | Semana 13 | Del 24 al 30 de marzo del 2013.

  14. van de Beek D, Brouwer MC, Thwaites G, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet. 2012; 380: 1693-1702.

  15. Yazdankhah SP, Kris P, Tzanakaki G, Kremastinou J, Kalmusova J, Musilek M et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol. 2004; 42: 5146-5153.




2020     |     www.medigraphic.com